Observing Patients with Advanced Renal Cell Carcinoma Before Systemic Therapy

Video

Moshe Ornstein, MD, explains which patients with RCC he observes for progression prior to systemic therapy.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Navigating High-Risk Disease in Multiple Myeloma: Treatment Strategies and the Role of ASCT
      Navigating High-Risk Disease in Multiple Myeloma: Treatment Strategies and the Role of ASCT
      IFM 2018-04: Dara-KRd Induction and Consolidation Plus Double Transplant in HR TE NDMM
      IFM 2018-04: Dara-KRd Induction and Consolidation Plus Double Transplant in HR TE NDMM
      Role of MRD Negativity Rates in Treatment Decision Making
      Role of MRD Negativity Rates in Treatment Decision Making
      IsKia: Isatuximab Plus KRd in Pre-Transplant Induction and Post-Transplant Consolidation in TE NDMM
      IsKia: Isatuximab Plus KRd in Pre-Transplant Induction and Post-Transplant Consolidation in TE NDMM
      Defining Success in Multiple Myeloma Induction and Maintenance
      Defining Success in Multiple Myeloma Induction and Maintenance
      PERSEUS: Daratumumab plus VRd in Newly Diagnosed Multiple Myeloma Patients
      PERSEUS: Daratumumab plus VRd in Newly Diagnosed Multiple Myeloma Patients
      Alexander I. Spira, MD, PhD, FACP, an expert on lung cancer
      HERTHENA-Lung01: HER3-DXd in Previously Treated Advanced EGFR-Mutated NSCLC
      Alexander I. Spira, MD, PhD, FACP, an expert on lung cancer
      MARIPOSA-2: Amivantamab, Lazertinib, and Chemotherapy in EGFR-Mutated Advanced NSCLC
      Joshua K. Sabari, MD, an expert on lung cancer
      TROPION-Lung05: Dato-DXd in Previously Treated NSCLC
      Joshua K. Sabari, MD, an expert on lung cancer
      MARIPOSA: Amivantamab Plus Lazertinib in EGFR-Mutated Advanced NSCLC
      Related Content
      Recap: CLEAR Trial Regimen as a Standard for Frontline Clear Cell RCC: Impressive Efficacy but Personalization Is Needed

      Recap: CLEAR Trial Regimen as a Standard for Frontline Clear Cell RCC: Impressive Efficacy but Personalization Is Needed

      ONCOLOGY Staff
      May 13th 2023
      Article

      A panel of experts discuss the updated results of the phase 3 CLEAR trial presented at the 2022 International Kidney Cancer Symposium.

      Lenvatinib Combined With Pembrolizumab or Everolimus Lengthens Survival in Advanced Renal Cell Carcinoma

      Lenvatinib Combined With Pembrolizumab or Everolimus Lengthens Survival in Advanced Renal Cell Carcinoma

      April 21st 2021
      Article

      This article reviews the results of the phase 3 KEYNOTE-581/CLEAR trial and features expert insights from trial investigators, Robert J. Motzer, MD, and Toni Choueiri, MD.